Chris Mauney, Senior Associate at NovaQuest Capital Management, has experience advancing a range of drug development and regulatory programs across diverse indications and therapeutic modalities. He is responsible for due diligence, structuring of investment opportunities, and post-close investment management.
Prior to joining NovaQuest, Dr. Mauney was a scientific and regulatory consultant with Syneos Health, a global contract research organization, with a focus on nonclinical development strategy. His earlier experiences include integrated product development with the mid-size contract research organization Rho; biomedical product development to address global public health challenges as a technical analyst with USAID; and postdoctoral training in biochemistry and biophysics.
Dr. Mauney earned a BA in English from Wake Forest University, a MS in Biotechnology from Johns Hopkins, MBA from Wake Forest University, and a PhD in Biochemistry and Molecular Biology from Wake Forest University.